NCT04900545

Effect of Genetic Polymorphisms on Response to Beta Blocker Therapy in Egyptian Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 80 (actual)
• Sponsor: Mohamed Saleh Fayed · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: —

Summary

Beta-blockers represent a cornerstone for the treatment of coronary artery disease (CAD). Their protective effect is based on the negative inotropic and chronotropic features, which have been tested in a large number of randomized controlled trials, both in patients with myocardial infarction (MI) and in those with stable angina, demonstrating a reduction of adverse cardiovascular events, a relief of symptoms and a reduction of myocardial ischemia However, considerable interpatient variability in response to β-blockers has been reported which indicates that a considerable proportion of β-blocker-treated patients do not achieve the warranted cardio protection with β- blockers. This highlights the importance of identifying biomarkers associated with variability in response to β-blockers to improve the current approach for β- blocker selection, which seems to be suboptimal. This study aims to study the effect of polymorphism in adrenergic beta receptors on beta-blocker response in Egyptian patients.

Conditions

• Acute Coronary Syndrome
• Hypertension

Timeline

• Start date: 2021-05-05
• Primary completion: 2021-05-25
• Completion: 2021-08-01
• First posted: 2021-05-25
• Last updated: 2022-12-01

Locations

1 site across 1 country: Egypt